Evaluation of a risk of malignancy index based on serum CA125, ultrasound findings and menopausal status in the pre-operative diagnosis of pelvic masses

BJOG: An International Journal of Obstetrics and Gynaecology

Volumn 103, Issue 8, 1996, Pages 826-831

  Tingulstad, Solveig ^a   Hagen, Bjørn ^a   Skjeldestad, Finn Egil ^a   Onsrud, Mathias ^a   Kiserud, Torvid ^a   Halvorsen, Tore ^a   Nustad, Kjell ^b  

^a TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN;

ADULT; ARTICLE; BENIGN TUMOR; CANCER RISK; CANCER STAGING; DIAGNOSTIC ACCURACY; ECHOGRAPHY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; MENOPAUSE; OVARY CANCER; PRIORITY JOURNAL;

ADULT; AGED; CA-125 ANTIGEN; FEMALE; HUMANS; LOGISTIC MODELS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; POSTMENOPAUSE; PREMENOPAUSE; PREOPERATIVE CARE; PROSPECTIVE STUDIES; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 0029744896     PISSN: 14700328     EISSN: 14710528     Source Type: Journal    
DOI: 10.1111/j.1471-0528.1996.tb09882.x     Document Type: Article

References (22)

1. Hacker NF, van der Burg MEL. Debulking and intervention surgery. Ann Oncol 1993; 4 (Suppl): 17–22.
2. Levin L, Lund B, Heintz AMP. An overview of multivariate analysis of prognostic variables with special reference to the role of cytoreductive surgery. Ann Oncol 1993; 4(Suppl): 23–29.
3. Kehoe S, Powell J, Wilson S, Woodman C. The influence of the operating surgeon’s specialisation on patient survival in ovarian carcinoma. Int J Cancer 1994; 70: 1014–1017.
4. Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG. A risk of malignancy index incorporating CA125, ultrasound and menopausal status for the accurate pre-operative diagnosis of ovarian cancer. Br J Obstet Gynaecol 1990; 97: 922–929.
5. Bourne T, Campbell S, Steer C, Whitehead MI, Collins WP. Transvaginal colour flow imaging: a possible new screening technique for ovarian cancer. BMJ 1989; 299: 1367–1370.
6. Kurjack A, Zalud I, Jurkovic D, Alfirevic Z, Miljan M. Transvaginal color doppler for the assessment of pelvic circulation. Acta Obstet Gynecol Scand 1989; 68: 131–135.
7. Fleischer A, Rogers WH, Rao BK, Kepple DM, Jones HW. Transvaginal color doppler sonography of ovarian masses with pathologic correlation. Ultrasound Obstet Gynecol 1991; 1: 275–278.
8. Kurjak A, Zalud I, Alfirevic Z. Evaluation of adnexal masses with transvaginal color ultrasound. J Ultrasound Med 1991; 10: 295–297.
9. Weiner Z, Thaler I, Beck D, Rottem S, Deutsch M, Brandes JM. Differentiating malignant from benign ovarian tumours with transvaginal color flow imaging. Obstet Gynecol 1991; 79: 159–162.
10. Einhorn N, Bast RC, Knapp RC, Tjernberg N, Zurawski VR. Preoperative evaluation of serum CA125 levels in patients with primary epithelial ovarian cancer. Obstet Gynecol 1986; 67: 414–416.
11. Zi-Xia C, Schwartz PE, Xinguo Li, Zhan Y. Evaluation of CA125 levels in differentiating malignant from benign tumors in patients with pelvic masses. Obstet Gynecol 1988; 72: 23–27.
12. Vasilev SA, Schlaerth JB, Campeau J, Morrow CP. Serum CAI25 levels in preoperative evaluation of pelvic masses. Obstet Gynecol 1988; 71: 751–755.
13. Gadducci A, Ferdeghini M, Prontera C et al. The concomitant determination of different tumor markers in patients with epithelial ovarian cancer and benign ovarian masses: relevance for differential diagnosis. Gynecol Oncol 1992; 44: 147–154.
14. McGuckin MA, Ramm LE, Joy GJ, Free KE, Ward BG. Preoperative discrimination between ovarian carcinoma, non-ovarian gynaecological malignancy and benign adnexal masses using serum levels of CA125 and the polymorphic epithelial mucin antigens CASA, OSA and MSA. Int J Gynecol Cancer 1992; 2: 118–128.
15. Jacobs IJ, Rivera H, Oram DH, Base RC. Differential diagnosis of ovarian cancer with tumour markers CA125, CA15–3 and TAG72.3. Br J Obstet Gynaecol 1993; 100: 1120–1124.
16. Finkler NJ, Benacerraf B, Lavin PT, Wojciechowski C, Knapp RC. Comparison of serum CA125, clinical impression, and ultrasound in the preoperative evaluation of ovarian masses. Obstet Gynecol 1988; 12: 659–664.
17. Malkasian GD, Knapp RC, Lavin PT et al. Preoperative evaluation of serum CA125 levels in premenopausal and post-menopausal patients with pelvic masses: discrimination of benign from malignant disease. Am J Obstet Gynecol 1988; 159: 341–346.
18. Davies AP, Jacobs I, Woolas R, Fish A, Oram D. The adnexal mass: benign or malignant? Evaluation of a risk of malignancy index. Br J Obstet Gynaecol 1993; 100: 927–931.
19. Pettersson F. Annual report on the results of treatment in gynecological cancer. Int J Gynecol Obstet 1990; 36 Suppl: 238–249.
20. The Cancer Registry of Norway, Institute for Epidemiological Cancer Research. 1995.
21. Granberg S, Wiklaud M, Jansson I. Macroscopic characterisation of ovarian tumors and the relation to the histological diagnosis: criteria to be used for ultrasound evaluation. Gynecol Oncol 1989; 35: 139–144.
22. Bourne T. Can ovarian masses be characterized using ultrasound Gynecol Oncol 1993; 51: 4–6.